Loading...
Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer.
Prelaj, Arsela Tay, Rebecca Ferrara, R Chaput, N Besse, B Califano, Raffaele
Prelaj, Arsela
Tay, Rebecca
Ferrara, R
Chaput, N
Besse, B
Califano, Raffaele
Citations
Altmetric:
Abstract
Immune checkpoint blockade has been a pivotal development in the management of advanced non-small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient selection and avoid toxicity in potential non-responders. This review will address the use and limitations of tumour programmed death-ligand 1 expression as a predictive biomarker and review emerging biomarker strategies specifically related to NSCLC including genetic alterations (tumour mutation burden, loss and gain activated mutations), tumour-related factors (tumour microenvironment) and factors related to the host immune system. Novel approaches in biomarker detection such as peripheral blood monitoring will also be reviewed.
Description
Date
2018
Publisher
Collections
Keywords
Type
Article
Citation
Prelaj A, Tay R, Ferrara R, Chaput N, Besse B, Califano R. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. Eur J Cancer. 2018 Dec 4;106:144-59.